SYT13在癌症中的研究进展

doi:10.11904/j.issn.1002-3070.2023.02.016

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (2): 181-184.doi: 10.11904/j.issn.1002-3070.2023.02.016

SYT13在癌症中的研究进展

张一丹^1,2, 钟锐^1,2, 孙振轩², 王腾^1,2 综述, 刘金涛¹ 审校

1.大连市中心医院甲状腺外科(大连 116033);
2.大连医科大学研究生院

收稿日期:2022-10-10 修回日期:2023-03-16 发布日期:2023-05-30
通讯作者: 刘金涛,E-mail:liujintao77@aliyun.com
作者简介:张一丹,女,(1995-),硕士研究生,从事甲状腺和乳腺肿瘤的临床研究。

Research progress of SYT13 in cancer

ZHANG Yidan^1,2, ZHONG Rui^1,2, SUN Zhenxuan², WANG Teng^1,2, LIU Jintao¹

1. Department of Thyroid Surgery,Dalian Municipal Central Hospital,Dalian 116033,China;
2. Graduate School of Dalian Medical University

Received:2022-10-10 Revised:2023-03-16 Published:2023-05-30

摘要/Abstract

摘要： SYT13是一种非典型的突触结合蛋白,位于11号染色体上,在心脏、肺、睾丸、脑、肾、脾和胰腺等器官中均有表达。越来越多的研究证实SYT13在多种癌症中异常表达。本文就SYT13在恶性肿瘤发生发展中的研究进展进行综述。

关键词: 突触结合蛋白, SYT13, 癌症, 预后

Abstract: SYT13 is an atypical synaptotagmins located on chromosome 11.It is expressed in the heart,lung,testis,brain,kidney,spleen,pancreas and other organs.More and more studies have confirmed that SYT13 is abnormally expressed in a variety of cancers.This article reviews the research progress of SYT13 in the occurrence and development of malignant tumors.

Key words: Synaptotagmins, SYT13, Cancer, Prognosis

中图分类号:

R730.2

张一丹, 钟锐, 孙振轩, 王腾, 刘金涛. SYT13在癌症中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 181-184.

ZHANG Yidan, ZHONG Rui, SUN Zhenxuan, WANG Teng, LIU Jintao. Research progress of SYT13 in cancer[J]. Journal of Practical Oncology, 2023, 37(2): 181-184.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I2/181

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Glavan G,Schliebs R,Zivin M.Synaptotagmins in neurodegeneration[J].Anat Rec(Hoboken),2009,292(12):1849-1862.
3 Wolfes AC,Dean C.The diversity of synaptotagmin isoforms[J].Curr Opin Neurobiol,2020,63:198-209.
4 Henry D,Joselevitch C,Matthews GG,et al.Expression and distribution of synaptotagmin family members in the zebrafish retina[J].J Comp Neurol,2022,530(4):705-728.
5 Xue R,Meng H,Yin J,et al.The role of calmodulin vs.synaptotagmin in exocytosis[J].Front Mol Neurosci,2021,14:691363.
6 Von Poser C,Südhof TC.Synaptotagmin 13:structure and expression of a novel synaptotagmin[J].Eur J Cell Biol,2001,80(1):41-47.
7 Nizzardo M,Taiana M,Rizzo F,et al.Synaptotagmin 13 is neuroprotective across motor neuron diseases[J].Acta Neuropathol,2020,139(5):837-853.
8 Ofori JK,Karagiannopoulos A,Barghouth M,et al.The highly expressed calcium-insensitive synaptotagmin-11 and synaptotagmin-13 modulate insulin secretion[J].Acta Physiol(Oxf),2022,236(1):e13857.
9 Han S,Hong S,Lee D,et al.Altered expression of synaptotagmin 13 mRNA in adult mouse brain after contextual fear conditioning[J].Biochem Biophys Res Commun,2012,425(4):880-885.
10 Nakanishi K,Kanda M,Umeda S,et al.The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer[J].Gastric Cancer,2019,22(6):1143-1152.
11 Kanda M,Shimizu D,Tanaka H,et al.Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer[J].Br J Surg,2018,105(10):1349-1358.
12 张雨生,孙博实,迟强.miR-138靶向SYT13对胃癌细胞侵袭和迁移的影响及机制研究[J].哈尔滨医科大学学报,2021,55(55):495-499.
13 Kanda M,Kasahara Y,Shimizu D,et al.Amido-bridged nucleic acid-modified antisense oligonucleotides targeting SYT13 to treat peritoneal metastasis of gastric cancer[J].Mol Ther Nucleic Acids,2020,22:791-802.
14 Zhu H,Wu TC,Chen WQ,et al.Screening for differentially expressed genes between left-and right-sided colon carcinoma by microarray analysis[J].Oncol Lett,2013,6(2):353-358.
15 Li Q,Zhang S,Hu M,et al.Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells[J].Int J Mol Med,2020,45(1):234-244.
16 Zhang YD,Zhong R,Liu JQ,et al.Role of synaptotagmin 13(SYT13)in promoting breast cancer and signaling pathways[J].Clin Transl Oncol,2023[Online ahead of print].
17 Ichikawa T,Shibata M,Inaishi T,et al.Synaptotagmin 13 is highly expressed in estrogen receptor-positive breast cancer[J].Curr Oncol,2021,28(5):4080-4092.
18 Skˇriˇcková J,Kadlec B,Venclíˇcek O,et al.Lung cancer[J].Cas Lek Cesk,2018,157(5):226-236.
19 Niu W,Jiang L.A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma[J].Math Biosci Eng,2021,18(5):6136-6154.
20 Zhang L,Fan B,Zheng Y,et al.Identification SYT13 as a novel biomarker in lung adenocarcinoma[J].J Cell Biochem,2020,121(2):963-973.
21 Bertino G,Demma S,Ardiri A,et al.The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies[J].Biomed Res Int,2015,2015:731469.
22 Jahn JE,Best DH,Coleman WB.Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition[J].Exp Mol Pathol,2010,89(3):209-216.
23 Jahn JE,Coleman WB.Re-expression of tumorigenicity after attenuation of human synaptotagmin 13 in a suppressed microcell hybrid cell line[J].Int J Oncol,2008,32(2):441-449.
24 Lu J,Liu Q,Zhu L,et al.Endothelial cell-specific molecule 1 drives cervical cancer progression[J].Cell Death Dis,2022,13(12):1043.

[1]	夏前林, 仇荣, 陆悦, 张琼, 杜玉珍. 肺腺癌m6A甲基化调控因子相关预后风险模型的构建及临床意义[J]. 实用肿瘤学杂志, 2023, 37(1): 39-45.
[2]	张娟, 魏东华, 尹惠萍, 马艳玲, 钱立庭. 安徽省癌症防控现状及城市癌症筛查模式探讨[J]. 实用肿瘤学杂志, 2023, 37(1): 79-82.
[3]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[4]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[5]	陈亚丽, 刘婷, 陈娟, 杜秋静. 癌症患者围术期肠道菌群与神经精神症状关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 468-471.
[6]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[7]	于承平, 崔永康, 李林强. eccDNA在癌症中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 255-258.
[8]	王洪英, 李岩, 韩鑫浩, 魏孝礼, 贾慧珣, 袁文娟, 张秋菊. 基于免疫相关lncRNAs的胃癌早期诊断和预后风险模型的构建和验证[J]. 实用肿瘤学杂志, 2022, 36(2): 119-126.
[9]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[10]	陈德嘉, 娄阁. 连接蛋白26在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 162-166.
[11]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[12]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[13]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[14]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[15]	黄妹妹, 罗瑞君, 翁一鸣, 阮鹏. 家族性癌症史患者一级亲属的需求研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 94-98.

SYT13在癌症中的研究进展

Research progress of SYT13 in cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价